Related Experiment Video
Updated: Jun 25, 2025

Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery
Published on: September 19, 2014
Targeted SERS Imaging and Intraoperative Real-Time Elimination of Microscopic Tumors for Improved Breast-Conserving
Yu Wen1,2, Ruoxuan Liu1, Yangcenzi Xie1
1School of Materials Science and Engineering, Central South University, Changsha, Hunan, 410083, China.
Abstract:
Breast-conserving surgery is the favorable option for breast cancer patients owing to its advantages of less aggressiveness and better cosmetic outcomes over mastectomy. However, it often suffers from postsurgical lethal recurrence due to the incomplete removal of microscopic tumors. Here, a surface-enhanced Raman scattering (SERS) surgical strategy is reported for precise delineation of tumor margins and intraoperative real-time elimination of microscopic tumor foci, which is capable of complete surgical removal of breast tumors and significantly improve the outcomes of breast-conserving surgery without local tumor recurrence. The technique is chiefly based on the human epidermal growth factor receptor 2 (HER2)-targeting SERS probes with integrated multifunctionalities of ultrahigh sensitive detection, significant HER2 expression suppression, cell proliferation inhibition, and superior photothermal ablation. In a HER2+ breast tumor mouse model, the remarkable capability of the SERS surgical strategy for complete removal of HER2+ breast tumors through SERS-guided surgical resection and intraoperative real-time photothermal elimination is demonstrated. The results show complete eradiation of HER2+ breast tumors without local recurrence, consequently delivering a 100% tumor-free survival. Expectedly, this SERS surgical strategy holds great promise for clinical treatment of HER2+ breast cancer with improved patients' survival.
Insights
This study introduces a novel surface-enhanced Raman scattering (SERS) surgical strategy for breast cancer. This technique precisely targets HER2+ tumors, enabling complete removal and preventing recurrence, significantly improving patient outcomes.
Area of Science:
- Oncology
- Biomedical Engineering
- Nanotechnology
Background:
- Breast-conserving surgery is preferred but risks tumor recurrence due to microscopic residual disease.
- Accurate tumor margin delineation and complete microscopic tumor removal are critical for surgical success.
Purpose of the Study:
- To develop and evaluate a surface-enhanced Raman scattering (SERS) surgical strategy for precise tumor margin delineation and intraoperative elimination of microscopic breast tumors.
- To assess the efficacy of HER2-targeting SERS probes in suppressing tumor growth and enabling photothermal ablation.
Main Methods:
- Development of multifunctional HER2-targeting SERS probes for sensitive detection and therapeutic intervention.
- Application of SERS-guided surgical resection combined with intraoperative photothermal ablation in a HER2+ breast tumor mouse model.
Main Results:
- The SERS strategy achieved precise delineation of tumor margins and real-time elimination of microscopic tumor foci.
- Complete eradication of HER2+ breast tumors was demonstrated, resulting in 100% tumor-free survival in the mouse model.
- The SERS probes exhibited ultrahigh sensitivity, HER2 expression suppression, cell proliferation inhibition, and effective photothermal ablation.
Conclusions:
- The developed SERS surgical strategy offers a promising approach for complete surgical removal of HER2+ breast tumors, significantly reducing local recurrence.
- This technique has the potential to improve outcomes and survival rates for patients undergoing breast-conserving surgery for HER2+ breast cancer.
More Related Videos
06:37Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology
Published on: October 20, 2010
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019